Metadata record for the published article: Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: A prospective study

<b>Summary</b>The data described in this metadata record underlie the figures, tables and supplementary files in the related manuscript: “Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: A prospective study”.<b>Data access</b>The data supporting the related manuscript are kept in institutional file storage on an internal server at Lunenfeld-Tanenbaum Research Institute. There are de-identification concerns in small, regionally restricted, clinical datasets which prevent these data being openly available, but data will be made available at reasonable request from the corresponding author for up to and including 5 years from publication of the related manuscript. For all data requests please contact: Dr David Cescon, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. [e-mail]<b>Data description</b>The data were gathered while investigating whether high BMI or 25-OH vitamin D levels were associated with higher estrogen levels in post-menopausal women receiving adjuvant letrozole, and while evaluating whether an increased dose of letrozole resulted in lower serum estrogens in women with BMI &gt; 25 kg/m2.The following three files underlie all figures, tables and supplementary files of the related manuscript: alateststatus.txt, abase.txt, alabswide.txt.<b>Ethics</b>The associated trial is registered at ClinicalTrials.gov NCT01669343. The study was approved by the Ontario Research Ethics Board (OCREB), as well as each participating centre. Use of the letrozole 5 mg dose was authorized by a Health Canada Clinical Trial Application.